Current evidence supports Retatrutide as a promising candidate for dual treatment of obesity and alcohol-related concerns
Until the FDA completes its review and officially approves the drug, access is generally limited to research use or participation in formal clinical trials under a licensed provider
That is more than 5 times the rate of the youngest adults, and nearly double the 12% average across all adults
Understanding these differences is essential for selecting the most appropriate option for individual patients
While some patients experience diarrhea, others develop constipation, and many notice changes in bowel frequency or consistency
Fragmented Competitive Landscape The T2D market is moderately fragmented, with multiple generics, biosimilars, and branded therapies competing for share